Clinical trialsMonoclonal antibodiesSmall moleculesAdvances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-伪 (infliximab, etanercept, adalimumab), IL-1 (anakinra...
I have studied and treated ankylosing spondylitis (AS) for almost 10 years. It’s a form of axial spondyloarthritis (axSpA). That’s a type of inflammatory arthritis that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis. In its early sta...
“汉利康®is the first biosimilar approved in China and its indication plan and corresponding clinical research have always been at the forefront of biosimilars. In addition to adalimumab 汉达远®, the approval for 汉利康®on rheumatoid arthritis is another milestone of Henlius in autoimmune diseas...
C4X Discovery has developed Taxonomy3, a unique method for analysing genetic datasets based on mathematics that is novel in drug discovery. When applied to a previously published rheumatoid arthritis GWAS dataset, Taxonomy3 identified many additional novel genetic signals associated with this autoimmune ...
that signal your cells to make more inflammation. One study found that people who took a JAK inhibitor for just over 3 months were twice as likely to have a strong response as those who took a placebo, or fake pill. Two drugs, tofacitinib and upadacitinib, are in clinical trials. We ...
CP-690550 has been tested in clinical trials for rheumatoid arthritis and prevention of allograft rejection.69 Interestingly, another tyrosine kinase inhibitor (imatinib mesylate), which is now the first line treatment of chronic myeloid leukemia, also plays a role in cell receptor signaling.70 ...
41Based on early clinical trials, BSO is considered safe but has limited therapeutic benefit for treating refractory malignancies.190To improve its clinical efficacy, researchers attempted to identify BSO-sensitive cancer types and patients, revealing that low GSH levels can serve as a marker for BSO...
Buchanan, W. W., Goldsmith, C. H., Grace, E. and Hanna, B. (1987). The MACTAR patient preference disability questionnaire — an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis.J. Rheumatol., 14, 446–451....
for rheumatoid arthritis was approved in the United States and European Union but not listed in China previously. 汉利康®launched innovative clinical trials on rheumatoid arthritis based on its existing treatment research, opening up a new path for domestic rheumatic immunotherapy with differentiated ...
Our knowledge regarding the pathogenesis of BP has increased greatly in the last few years, leading to the development of newer targets for therapy. In addition to the latest clinical trials discussed in this review and previous ones [6], future approaches are being considered towards the ...